First oral GLP-1 for weight loss approved, priced from $149

An oral GLP-1 agent received FDA approval in April 2026 and reached pharmacies at cash prices reported from around $149 per month with manufacturer support.

It does not match injectable tirzepatide on effect size. The trade is convenience and price against magnitude.

For patients who will not inject, it is the most significant option to appear in years.

What this changes for what you pay

Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.

The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.

How to verify this yourself

Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.

Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 16 cash prices spanning $215 to $597.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 16 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Eight to twelve weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

What the dose ladder means for your bill

The approved ladder runs 2.5, 5, 7.5, 10, 12.5 and 15 mg weekly. Clinical trials studied 5, 10 and 15 mg as maintenance arms; the intermediate steps exist for titration rather than as targets. Where a person settles is a clinical decision driven by response and tolerability, not a preference.

That matters commercially because a dose-scaled programme is quoting you a price for a decision your prescriber has not made yet. If you settle at 15 mg on a programme that reprices at every step, you will pay materially more than the figure that attracted you. If you settle at 5 mg, you may pay less than a flat programme would charge.

Flat pricing is therefore worst value at the bottom of the ladder and best at the top. It is less a lower price than insurance against an outcome nobody can predict at signup. The cheapest flat option we verify is NexLife at $215 a month all-in.

Compounded is not a generic, and the difference is technical

A generic medicine has demonstrated bioequivalence to a reference product and been approved on that basis. A compounded preparation has done neither. It contains the same active molecule, but the formulation, concentration, excipients, container and beyond-use dating are decisions made by the compounding pharmacy rather than specifications reviewed by a regulator.

Practically, that means two vials of compounded tirzepatide from different pharmacies are not necessarily interchangeable. Concentration varies between operations, which is why dosing instructions are given in units or millilitres rather than by the pen click a Zepbound user would recognise, and why switching programmes mid-course requires confirming the new concentration rather than assuming it.

None of that makes compounding illegitimate. It does move a layer of quality assurance from a federal review process onto a pharmacy you can, and should, check.

Where the evidence stops

The trial evidence for tirzepatide concerns the approved product at studied doses. It does not extend to compounded preparations, to microdosing schedules marketed as a cheaper entry point, or to combination vials with added vitamins. Those may be reasonable in practice, but the evidence base does not follow them.

Anyone citing trial outcomes to sell a compounded preparation is borrowing credibility from a product they are not dispensing. The honest framing is that the molecule has strong evidence behind it and the specific preparation in the vial has the pharmacy's assurance behind it.